Furthermore, the MYC-mediated miR-29 repression mechanism for the therapy of aggressive B-cell malignancies (B-cell malignancies is the synonym of chronic lymphocytic leukemia according to Medical Subject Headings (MeSH) [44]) by applying the HDAC3 and EZH2 as therapeutic targets [45] was reported. This evidence concerns the gene MYC and B-cell chronic lymphocytic leukemia.